Streetbeat News

Regulatory

YCBD

cbdMD, Inc. (NYSE:YCBD) has received a notice of noncompliance from the NYSE American due to not meeting the continued listing standards, specifically having stockholders' equity below $4 million. The company must submit a compliance plan by July 5, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 11:26 pm

ICCH

Trading for ICCH was halted at 6:25:00 p.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 10:25 pm

CLIR

ClearSign Technologies announced that the position of Chairman of the Board has been vacated, effective immediately, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 9:33 pm

SERV

Serve Robotics has filed a prospectus with the SEC to register and allow the resale of up to 4.8 million shares of its common stock by selling stockholders.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 9:24 pm

ROMA

Roma Green Finance has filed for a best efforts self-underwritten offering of up to 3.6 million ordinary shares, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 9:24 pm

NVAC

NorthView Acquisition Corporation (NASDAQ:NVAC) has received a notice from Nasdaq for failing to file its Form 10-Q for the period ended March 31, 2024, which puts it out of compliance with Nasdaq Listing Rule 5250(c)(1).

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 9:14 pm

RBT

The New York Stock Exchange (NYSE) has announced that it will commence delisting proceedings against Rubicon Technologies (RBT). This decision follows the company's failure to meet the NYSE's continued listing standards.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 8:47 pm

DOGZ

Dogness International has filed a prospectus with the SEC for the potential resale of up to 2 million Class A common shares by selling shareholders.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 8:34 pm

CDIO

Cardio Diagnostics Holdings received a notice from Nasdaq on June 3, indicating non-compliance with Nasdaq Listing Rule 5550(a)(2).

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 8:32 pm

GSK

SWTX

SpringWorks Therapeutics announced that the termination of a certain agreement does not affect its rights to continue developing or commercializing its products or product candidates. The company also expects that GSK will continue ongoing clinical trials under the existing license agreement.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 8:26 pm